Artículos por temáticas

Natural Terpenoids as Neuroinflammatory Inhibitors in LPS-stimulated BV-2 Microglia

Xu Y, Wei H, Gao J.

Mini Rev Med Chem. 2021;21(4):520-534. doi: 10.2174/1389557519666190611124539.

Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers

Ma LY, Tian Y, Pan CR, Chen ZL, Ling Y, Ren K, Li JS, Feng T.

Front Aging Neurosci. 2021 Jan 25;12:627199. doi: 10.3389/fnagi.2020.627199. eCollection 2020.

Impact of anticholinergic drugs withdrawal on motor function in patients with Parkinson's disease

Saeedi Y, Ghadimi M, Rohani M, Emamikhah M, Shahidi G, Moghaddasi M, Habibi SAH.

Clin Neurol Neurosurg. 2021 Mar;202:106480. doi: 10.1016/j.clineuro.2021.106480. Epub 2021 Jan 8.

Associations of IL-1β and IL-6 gene polymorphisms with Parkinson's disease

Li N, Wang JX, Huo TT, Zhao JR, Wang TJ.

Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):890-897. doi: 10.26355/eurrev_202101_24657.

Health-Related Quality of Life for Parkinson's Disease Patients and Their Caregivers

Lubomski M, Davis RL, Sue CM.

J Mov Disord. 2021 Jan;14(1):42-52. doi: 10.14802/jmd.20079. Epub 2021 Jan 12.

Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease

Forbes E, Tropea TF, Mantri S, Xie SX, Morley JF.

Mov Disord Clin Pract. 2021 Jan 20;8(2):254-263. doi: 10.1002/mdc3.13143. eCollection 2021 Feb.

Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway

Vallée A, Vallée JN, Lecarpentier Y.

Cells. 2021 Jan 25;10(2):230. doi: 10.3390/cells10020230.

The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway

Kambey PA, Chengcheng M, Xiaoxiao G, Abdulrahman AA, Kanwore K, Nadeem I, Jiao W, Gao D.

Metab Brain Dis. 2021 Apr;36(4):609-625. doi: 10.1007/s11011-021-00670-2. Epub 2021 Jan 28.

Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson's Disease

Levstek T, Redenšek S, Trošt M, Dolžan V, Podkrajšek KT.

Antioxidants (Basel). 2021 Jan 19;10(1):137. doi: 10.3390/antiox10010137.

Hand Function as Predictor of Motor Symptom Severity in Individuals with Parkinson's Disease

Paz TDSR, de Britto VLS, Yamaguchi B, Israel VL, Swarowsky A, Lourenço Correa C.

Gerontology. 2021 Jan 19:1-8. doi: 10.1159/000511910. Online ahead of print.

Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson's disease: a systematic review

Xu Y, He Q, Wang M, Gao Y, Liu X, Li D, Xiong B, Wang W.

Neurosurg Rev. 2021 Feb;44(1):115-127. doi: 10.1007/s10143-019-01216-y. Epub 2019 Dec 9.

Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease

Cavallieri F, Budriesi C, Gessani A, Contardi S, Fioravanti V, Menozzi E, Pinto S, Moro E, Valzania F, Antonelli F.

Front Neurol. 2021 Feb 5;11:616062. doi: 10.3389/fneur.2020.616062. eCollection 2020.

Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease

Madsen DA, Schmidt SI, Blaabjerg M, Meyer M.

Cells. 2021 Jan 31;10(2):283. doi: 10.3390/cells10020283.

Istradefylline - a first generation adenosine A(2A) antagonist for the treatment of Parkinson's disease

Jenner P, Mori A, Aradi SD, Hauser RA.

Expert Rev Neurother. 2021 Feb 22:1-17. doi: 10.1080/14737175.2021.1880896. Online ahead of print.

How Do Patients With Parkinson's Disease Approach Advance Care Planning? A UK-Based Mixed Methods Study

Churm D, Dickinson C, Robinson L, Paes P, Cronin T, Walker R.

J Geriatr Psychiatry Neurol. 2021 Jan 19:891988720988917. doi: 10.1177/0891988720988917. Online ahead of print.